The DOI matches its Crossref record; 717 of the 717 references it cites were found in a registry or an index.
ImmunoPET: Concept, Design, and Applications
Open accessAbstract
Immuno-positron emission tomography (immunoPET) is a paradigm-shifting molecular imaging modality combining the superior targeting specificity of monoclonal antibody (mAb) and the inherent sensitivity of PET technique. A variety of radionuclides and mAbs have been exploited to develop immunoPET probes, which has been driven by the development and optimization of radiochemistry and conjugation strategies. In addition, tumor-targeting vectors with a short circulation time (e.g., Nanobody) or with an enhanced binding affinity (e.g., bispecific antibody) are being used to design novel immunoPET probes. Accordingly, several immunoPET probes, such as 89 Zr-Df-pertuzumab and 89 Zr-atezolizumab, have been successfully translated for clinical use. By noninvasively and dynamically revealing the expression of heterogeneous tumor antigens, immunoPET imaging is gradually changing the theranostic landscape of several types of malignancies. ImmunoPET is the method of choice for imaging specific tumor markers, immune cells, immune checkpoints, and inflammatory processes. Furthermore, the integration of immunoPET imaging in antibody drug development is of substantial significance because it provides pivotal information regarding antibody targeting abilities and distribution profiles. Herein, we present the latest immunoPET imaging strategies and their preclinical and clinical applications. We also emphasize current conjugation strategies that can be leveraged to develop next-generation immunoPET probes. Lastly, we discuss practical considerations to tune the development and translation of immunoPET imaging strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 601–717 of 717
Knowles, S. M., Tavaré, R., Zettlitz, K. A., Rochefort, M. M., Salazar, F. B., Jiang, Z. K., Reiter, R. E., & Wu, A. M. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1452 · Cited by 38
Krämer-Marek, G., Gijsen, M., Kiesewetter, D. O., Bennett, R., Roxanis, I., Zieliński, R., Kong, A. H., & Capala, J. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.096685 · Cited by 38
Green, D. J., Frayo, S. L., Lin, Y., Hamlin, D. K., Fisher, D. R., Frost, S. H. L., Kenoyer, A. L., Hylarides, M. D., Gopal, A. K., Gooley, T. A., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0571 · Cited by 38
Therapy assessment in prostate cancer using choline and PSMA PET/CT
Ceci, F., Herrmann, K., Hadaschik, B. A., Castellucci, P., & Fanti, S. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3723-3 · Cited by 38
Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody
Huang, S., Li, F., Liu, H., Ye, P., Fan, X., Xinqiu, Y., Zhi-Dan, W. U., Chen, J., Jin, C., Shen, B., et al. (2018) · mAbs · doi:10.1080/19420862.2018.1486946 · Cited by 38
Sharkey, R. M., Karacay, H., McBride, W. J., Rossi, E. A., Chang, C., & Goldenberg, D. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1087 · Cited by 37
Design and Applications of Bispecific Heterodimers: Molecular Imaging and beyond
Luo, H., Hong, H., Yang, S. P., & Cai, W. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500115x · Cited by 37
Self-citationvan der Geest, T., Laverman, P., Gerrits, D., Walgreen, B., Helsen, M. M. A., Klein, C., Nayak, T. K., Storm, G., Metselaar, J. M., Koenders, M. I., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.177931 · Cited by 37
Summer, D., Garousi, J., Oroujeni, M., Mitran, B., Andersson, K. G., Vorobyeva, A., Löfblom, J., Orlova, A., Максимилианович, Т. В., & Decristoforo, C. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00787 · Cited by 37
Alt, K., Paterson, B. M., Westein, E., Rudd, S. E., Poniger, S. S., Jagdale, S., Ardipradja, K., Connell, T. U., Krippner, G. Y., Nair, A. K. N., et al. (2015) · Angewandte Chemie · doi:10.1002/ange.201411507 · Cited by 37
Trousil, S., Hoppmann, S., Nguyen, Q., Kaliszczak, M. A., Tomasi, G., Iveson, P. B., Hiscock, D., & Aboagye, E. O. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2421 · Cited by 36
Preclinical 89Zr Immuno-PET of High-Grade Serous Ovarian Cancer and Lymph Node Metastasis
Sharma, S. K., Sevak, K. K., Monette, S., Carlin, S. D., Knight, J. C., Wuest, F. R., Sala, E., Zeglis, B. M., & Lewis, J. S. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.167072 · Cited by 36
Dual Targeting of Tissue Factor and CD105 for Preclinical PET Imaging of Pancreatic Cancer
Luo, H., England, C. G., Shi, S., Graves, S. A., Hernandez, R., Liu, B., Theuer, C. P., Wong, H. C., Nickles, R. J., & Cai, W. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2054 · Cited by 36
Self-citation89Zr-Onartuzumab PET imaging of c-MET receptor dynamics
Pool, M., van Scheltinga, A. G. T. T., Kol, A., Giesen, D., de Vries, E. G. E., & Hooge, M. N. L. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3672-x · Cited by 36
CD38 as a PET Imaging Target in Lung Cancer
Ehlerding, E. B., England, C. G., Jiang, D., Graves, S. A., Kang, L., Lacognata, S., Barnhart, T. E., & Cai, W. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00298 · Cited by 36
Self-citationImmuno-PET of Innate Immune Markers CD11b and IL-1β Detects Inflammation in Murine Colitis
Dmochowska, N., Tieu, W., Keller, M., Wardill, H. R., Mavrangelos, C., Campaniello, M. A., Takhar, P., & Hughes, P. A. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.219287 · Cited by 36
van Rij, C. M., Frielink, C., Goldenberg, D. M., Sharkey, R. M., Lütje, S., McBride, W. J., Oyen, W. J. G., & Boerman, O. C. (2014) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2014.1660 · Cited by 35
Do, K. T., Cao, L., Kang, Z., Türkbey, B., Lindenberg, M. L., Larkins, E. A., Holkova, B., Steinberg, S. M., Raffeld, M. A., Peer, C. J., et al. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2015.02.007 · Cited by 35
PET of HER2 Expression with a Novel 18 FAl Labeled Affibody
Xu, Y., Bai, Z., Huang, Q., et al. (2017) · Journal of Cancer · doi:10.7150/jca.18070 · Cited by 35
Yusufi, N., Mall, S., Bianchi, H. D. O., Steiger, K., Reder, S., Klar, R., Audehm, S., Mustafa, M., Nekolla, S. G., Peschel, C., et al. (2017) · Theranostics · doi:10.7150/thno.17994 · Cited by 35
El‐Sayed, A., Bernhard, W., Barreto, K., Gonzalez, C., Hill, W., Pastushok, L., Fonge, H., & Geyer, C. R. (2018) · Theranostics · doi:10.7150/thno.24252 · Cited by 35
Linssen, M. D., ter Weele, E. J., Allersma, D. P., Hooge, M. N. L., van Dam, G. M., Jorritsma‐Smit, A., & Nagengast, W. B. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.216556 · Cited by 35
Frost, S. H. L., Miller, B. W., Bäck, T. A., Santos, E. B., Hamlin, D. K., Knoblaugh, S. E., Frayo, S. L., Kenoyer, A. L., Storb, R. F., Press, O. W., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.162388 · Cited by 34
Sun, H., England, C. G., Hernandez, R. T., Graves, S. A., Majewski, R. L., Kamkaew, A., Jiang, D., Barnhart, T. E., Yang, Y., & Cai, W. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3442-1 · Cited by 34
Self-citationWaaijer, S. J. H., Warnders, F. J., Stienen, S., Friedrich, M., Sternjak, A., Cheung, H. K., van Scheltinga, A. G. T. T., Schröder, C. P., de Vries, E. G. E., & Hooge, M. N. L. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0786 · Cited by 34
Novel Quantitative PET Techniques for Clinical Decision Support in Oncology
Zaidi, H., Alavi, A. A., & Naqa, I. E. (2018) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2018.07.003 · Cited by 34
Antibody‐Based Tracers for PET/SPECT Imaging of Chronic Inflammatory Diseases
Lee, H. J., Ehlerding, E. B., & Cai, W. (2018) · ChemBioChem · doi:10.1002/cbic.201800429 · Cited by 34
Self-citationZettlitz, K. A., Waldmann, C. M., Tsai, W. K., Tavaré, R., Collins, J., Murphy, J. M., & Wu, A. M. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.223560 · Cited by 34
Tieu, W., Hollis, C. A., Kuan, K., Takhar, P., Stuckings, M., Spooner, N. A., & Malinconico, M. (2019) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2019.07.005 · Cited by 34
Li, L., Jaraquemada-Peláez, M. D. G., Aluicio‐Sarduy, E., Wang, X., Jiang, D., Saekheie, M., Kuo, H., Barnhart, T. E., Cai, W., Radchenko, V., et al. (2020) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.9b03347 · Cited by 34
Self-citationImmunoPET helps predicting the efficacy of antibody-drug conjugates targeting TENB2 and STEAP1
Williams, S., Ogasawara, A. K., Tinianow, J. N., Flores, J. E., Kan, D., Lau, J., Go, M., Vanderbilt, A. N., Gill, H. S., Li, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8390 · Cited by 33
Nováková, Z., Foss, C. A., Copeland, B. T., et al. (2017) · The Prostate · doi:10.1002/pros.23311 · Cited by 33
Zhou, Z., McDougald, D. L., Devoogdt, N., Zalutsky, M. R., & Vaidyanathan, G. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00951 · Cited by 33
PET Imaging of HER2-Positive Tumors with Cu-64-Labeled Affibody Molecules
Qi, S., Hoppmann, S., Xu, Y., & Cheng, Z. (2019) · Molecular Imaging and Biology · doi:10.1007/s11307-018-01310-5 · Cited by 33
Pereira, P. M. R., Mandleywala, K., Ragupathi, A., Carter, L. M., Goos, J. A. C. M., Janjigian, Y. Y., & Lewis, J. S. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.225813 · Cited by 33
Enhanced immunoPET of ALCAM-positive colorectal carcinoma using site-specific 64Cu-DOTA conjugation
Tavaré, R., Wu, W.-J., Zettlitz, K. A., Salazar, F. B., McCabe, K. E., Marks, J. D., & Wu, A. M. (2014) · Protein Engineering Design and Selection · doi:10.1093/protein/gzu030 · Cited by 32
Basuli, F., Zhang, X., Woodroofe, C. C., Jagoda, E. M., Choyke, P. L., & Swenson, R. E. (2016) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3487 · Cited by 32
Alsaid, H., Skedzielewski, T., Rambo, M. V., Hunsinger, K., Hoang, B. Q., Fieles, W. E., Long, E. R., Tunstead, J. R., Vugts, D. J., Cleveland, M., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176075 · Cited by 32
Pretargeted Immuno-PET Based on Bioorthogonal Chemistry for Imaging EGFR Positive Colorectal Cancer
Shi, X., Gao, K., Huang, H., & Gao, R. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00023 · Cited by 32
Zettlitz, K. A., Tavaré, R., Tsai, W. K., Yamada, R. E., Ha, N. S., Collins, J., van Dam, R. M., Timmerman, J. M., & Wu, A. M. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4214-x · Cited by 32
Park, S. I., Shenoi, J., Frayo, S. L., Hamlin, D. K., Lin, Y., Wilbur, D. S., Stayton, P. S., Orgun, N. N., Hylarides, M. D., Buchegger, F., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1204 · Cited by 31
64Cu-p-NH2-Bn-DOTA-hu14.18K322A, a PET Radiotracer Targeting Neuroblastoma and Melanoma
Vāvere, A. L., Butch, E. R., Dearling, J. L. J., Packard, A. B., Navid, F., Shulkin, B. L., Barfield, R. C., & Snyder, S. E. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.104208 · Cited by 31
Annotating STEAP1 Regulation in Prostate Cancer with 89Zr Immuno-PET
Doran, M. G., Watson, P. A., Cheal, S. M., Spratt, D. E., Wongvipat, J., Steckler, J. M., Carrasquillo, J. A., Evans, M. J., & Lewis, J. S. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.145185 · Cited by 31
Adewuyi, E. E., Lopez-Campistrous, A., Tang, X., Brindley, D. N., & McMullen, T. P. W. (2016) · Oncotarget · doi:10.18632/oncotarget.13299 · Cited by 31
Candidate immune biomarkers for radioimmunotherapy
Lévy, A., Nigro, G., Sansonetti, P. J., & Deutsch, É. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.02.006 · Cited by 31
Small-Animal PET/CT Imaging of Local and Systemic Immune Response Using64Cu-αCD11b
Cao, Q., Huang, Q., Mohan, C., & Li, C. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.220350 · Cited by 31
Multimodal imaging of pancreatic beta cells in vivo by targeting transmembrane protein 27 (TMEM27)
Vats, D., Wang, H., Esterházy, D., Dikaiou, K., Danzer, C. F., Honer, M., Stuker, F., Matile, H., Migliorini, C., Fischer, E., et al. (2012) · Diabetologia · doi:10.1007/s00125-012-2605-2 · Cited by 30
Dourado, K. M. C., Baik, J., Oliveira, V. K. P., Beltrame, M. P., Yamamoto, A., Theuer, C. P., Figueiredo, C. A., Verneris, M. R., & Perlingeiro, R. C. R. (2017) · Blood · doi:10.1182/blood-2017-01-763581 · Cited by 30
David, T., Hlinová, V., Kubíček, V., Bergmann, R., Striese, F., Berndt, N., Szöllősi, D., Kovács, T., Máthé, D., Bachmann, M. P., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00932 · Cited by 30
Guo, X., Zhu, H., Zhou, N., Chen, Z., Liu, T., Liu, F., Xu, X., Jin, H., Shen, L., Gao, J., et al. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00673 · Cited by 30
Natarajan, A., & Gambhir, S. S. (2014) · Molecular Imaging and Biology · doi:10.1007/s11307-014-0810-8 · Cited by 29
Zhang, Y., Hong, H., Nayak, T. R., Valdovinos, H. F., Myklejord, D. V., Theuer, C. P., Barnhart, T. E., & Cai, W. (2013) · Angiogenesis · doi:10.1007/s10456-013-9344-y · Cited by 29
Self-citationLopez-Campistrous, A., Adewuyi, E. E., Benesch, M. G. K., Ko, Y. M., Lai, R. L., Thiesen, A., Dewald, J. W., Wang, P., Chu, K. P.-M., Ghosh, S., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.09.007 · Cited by 29
The Use of Microdosing in the Development of Small Organic and Protein Therapeutics
Bergström, M. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.188037 · Cited by 29
“Albumin Hitchhiking” with an Evans Blue Analog for Cancer Theranostics
Ehlerding, E. B., Lan, X., & Cai, W. (2017) · Theranostics · doi:10.7150/thno.24183 · Cited by 29
Self-citationF8-IL10: A New Potential Antirheumatic Drug Evaluated by a PET-Guided Translational Approach
Bruijnen, S. T. G., Chandrupatla, D. M. S. H., Giovannoni, L., Neri, D., Vugts, D. J., Huisman, M. C., Hoekstra, O. S., Musters, R. J. P., Lammertsma, A. A., van Dongen, G. A. M. S., et al. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00982 · Cited by 29
Li, D., Zou, S., Cheng, S., Song, S., Wang, P., & Zhu, X. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00307 · Cited by 29
Demine, S., Ribeiro, R. S. G., Thévenet, J., Marselli, L., Marchetti, P., Pattou, F. N., Kerr-Conte, J. A., Devoogdt, N., & Eizirik, D. L. (2019) · Diabetologia · doi:10.1007/s00125-019-05068-5 · Cited by 29
Su, X., Cheng, K., Liu, Y., Hu, X., Meng, S., & Cheng, Z. (2015) · Amino Acids · doi:10.1007/s00726-015-1975-4 · Cited by 28
Vos, J. D., Mathijs, I., Xavier, C., Massa, S., Wernery, U., Bouwens, L., Lahoutte, T., Muyldermans, S., & Devoogdt, N. (2014) · Molecular Imaging and Biology · doi:10.1007/s11307-014-0731-6 · Cited by 28
Dearling, J. L. J., Park, E. J., Dunning, P. S., Baker, A., Fahey, F. H., Treves, S. T., Soriano, S. G., Shimaoka, M., Packard, A. B., & Peer, D. (2010) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21231 · Cited by 28
Schwarz, S. W., Decristoforo, C., Goodbody, A. E., Singhal, N., Saliba, S., Ruddock, P. S., Zukotynski, K., & Ross, A. A. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.209460 · Cited by 28
Schoffelen, R., van der Graaf, W. T. A., Sharkey, R. M., Franssen, G. M., McBride, W. J., Chang, C., Laverman, P., Goldenberg, D. M., Oyen, W. J. G., & Boerman, O. C. (2012) · EJNMMI Research · doi:10.1186/2191-219x-2-5 · Cited by 27
Orcutt, K. D., Adams, G. P., Wu, A. M., Silva, M. D., Harwell, C., Hoppin, J., Matsumura, M., Kotsuma, M., Greenberg, J., Scott, A. M., et al. (2017) · Molecular Imaging and Biology · doi:10.1007/s11307-016-1041-y · Cited by 27
van Zanten, S. E. M. V., Sewing, A. C. P., van Lingen, A., Hoekstra, O. S., Wesseling, P., Meel, M. H., van Vuurden, D. G., Kaspers, G. J. L., Hulleman, E., & Bugiani, M. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.197897 · Cited by 27
Muns, J. A., Montserrat, V., Houthoff, H.-J., van der Schilden, K., Zwaagstra, O., Sijbrandi, N. J., Merkul, E., & van Dongen, G. A. M. S. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.206672 · Cited by 27
Banerjee, S. R., Kumar, V., Lisok, A., Plyku, D., Nováková, Z., Brummet, M. E., Wharram, B. L., Bařinka, C., Hobbs, R. F., & Pomper, M. G. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.214403 · Cited by 27
van Rij, C. M., Frielink, C., Goldenberg, D. M., Sharkey, R. M., Franssen, G. M., Lütje, S., McBride, W. J., Oyen, W. J. G., & Boerman, O. C. (2014) · Molecular Imaging and Biology · doi:10.1007/s11307-014-0772-x · Cited by 26
Thorek, D. L. J., Watson, P. A., Lee, S.-G., Ku, A. T., Bournazos, S., Braun, K., Kim, K., Sjöström, K., Doran, M. G., Lamminmäki, U., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2335 · Cited by 26
Martins, C. D., Pieve, C. D., Burley, T. A., Smith, R., Ciobota, D. M., Allott, L., Harrington, K. J., Oyen, W. J. G., Smith, G. S. T., & Krämer-Marek, G. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2754 · Cited by 26
86/90Y-Based Theranostics Targeting Angiogenesis in a Murine Breast Cancer Model
Ehlerding, E. B., Ferreira, C. A., Aluicio‐Sarduy, E., Jiang, D., Lee, H. J., Theuer, C. P., Engle, J. W., & Cai, W. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00133 · Cited by 26
Self-citationPhase I Study of a CD45-Targeted Antibody–Radionuclide Conjugate for High-Risk Lymphoma
Cassaday, R. D., Press, O. W., Pagel, J. M., Rajendran, J. G., Gooley, T. A., Fisher, D. R., Holmberg, L., Miyaoka, R. S., Sandmaier, B. M., Green, D. J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1567 · Cited by 26
HER2-Targeted PET Imaging and Therapy of Hyaluronan-Masked HER2-Overexpressing Breast Cancer
Pereira, P. M. R., Ragupathi, A., Shmuel, S., Mandleywala, K., Viola, N. T., & Lewis, J. S. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b01091 · Cited by 26
Targeting angiogenesis for radioimmunotherapy with a 177Lu-labeled antibody
Ehlerding, E. B., Lacognata, S., Jiang, D., Ferreira, C. A., Goel, S., Hernandez, R. T., Jeffery, J. J., Theuer, C. P., & Cai, W. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3793-2 · Cited by 25
Self-citationLong, N. E., Sullivan, B. J., Ding, H., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.002538 · Cited by 25
SiFA‐Modified Phenylalanine: A Key Compound for the Efficient Synthesis of 18F‐Labelled Peptides
Iovkova, L., Könning, D., Wängler, B., Schirrmacher, R., Schoof, S., Arndt, H., & Jurkschat, K. (2011) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.201100142 · Cited by 24
Deshayes, E., Ladjohounlou, R., Fur, P. L., Pichard, A., Lozza, C., Boudousq, V., Sevestre, S., Jarlier, M., Kashani, R., Joanna, K., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.208611 · Cited by 24
Karacay, H., Sharkey, R. M., McBride, W. J., Rossi, E. A., Chang, C., & Goldenberg, D. M. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.083568 · Cited by 23
Velikyan, I., Wennborg, A., Feldwisch, J., Lindman, H., Carlsson, J., & Sørensen, J. C. H. (2016) · PubMed Central · Cited by 23
Azhdarinia, A., Voss, J., Ghosh, S. C., Simien, J., Vargas, S. H., Cui, J., Yu, W., Liu, Q., & Carmon, K. S. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00275 · Cited by 23
Novel Target Selection for Nuclear Medicine Studies
Lee, S. T., Burvenich, I. J. G., & Scott, A. M. (2019) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2019.06.004 · Cited by 23
MANOTA: a promising bifunctional chelating agent for copper-64 immunoPET
Moreau, M., Poty, S., Vrigneaud, J., WALKER, P. M., Guillemin, M., Raguin, O., Oudot, A., Bernhard, C., Goze, C., Boschetti, F., et al. (2017) · Dalton Transactions · doi:10.1039/c7dt01772c · Cited by 22
89Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment
Pool, M., Kol, A., de Jong, S., de Vries, E. G. E., Hooge, M. N. L., & van Scheltinga, A. G. T. T. (2017) · mAbs · doi:10.1080/19420862.2017.1371382 · Cited by 22
Lütje, S., Gerrits, D., Molkenboer‐Kuenen, J. D. M., Herrmann, K., Fracasso, G., Colombatti, M., Boerman, O. C., & Heskamp, S. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.196279 · Cited by 22
Ríos, X., Compte, M., Gómez‐Vallejo, V., Cossío, U., Baz, Z., Morcillo, M. Á., Ramos‐Cabrer, P., Álvarez‐Vallina, L., & Llop, J. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b01006 · Cited by 22
Cai, H., Shi, Q., Tang, Y., Chen, L., Chen, Y., Tao, Z., Yang, H., Xie, F., Wu, X., Liu, N., et al. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b01317 · Cited by 22
Huang, H.-F., Zhu, H., Li, G., Xie, Q., Yang, X., Xu, X., Tian, X., Wan, Y., & Yang, Z. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00539 · Cited by 22
Ding, H., Carlton, M. M., Povoski, S. P., Milum, K., Kumar, K., Kothandaraman, S., Hinkle, G. H., Colcher, D. M., Brody, R., Davis, P. D., et al. (2013) · Bioconjugate Chemistry · doi:10.1021/bc400375f · Cited by 21
Jacobson, O., Li, Q., Chen, H., Niu, G., Kiesewetter, D. O., Xu, L., Cook, K. E., Yang, G. J., Dall’Acqua, W. F., Tsui, P., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.192245 · Cited by 21
England, C. G., Jiang, D., Hernandez, R. T., Sun, H., Valdovinos, H. F., Ehlerding, E. B., Engle, J. W., Yang, Y., Huang, P., & Cai, W. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00216 · Cited by 21
Self-citationDual-labeled pertuzumab for multimodality image-guided ovarian tumor resection.
Lee, H. J., Ehlerding, E. B., Jiang, D., Barnhart, T. E., Cao, T., Wei, W., Ferreira, C. A., Huang, P., Engle, J. W., & Cai, W. (2019) · PubMed · Cited by 21
Self-citationHER2-targeted multimodal imaging of anaplastic thyroid cancer.
Wei, W., Jiang, D., Rosenkrans, Z. T., Barnhart, T. E., Engle, J. W., Luo, Q., & Cai, W. (2019) · PubMed Central · Cited by 21
Self-citationImaging of CD47 Expression in Xenograft and Allograft Tumor Models
Zheleznyak, A., Ikotun, O. F., Dimitry, J. M., Frazier, W. A., & Lapi, S. E. (2013) · Molecular Imaging · doi:10.2310/7290.2013.00069 · Cited by 20
Dearling, J. L. J., Daka, A., Veiga, N., Peer, D., & Packard, A. B. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000677 · Cited by 20
Warnders, F.-J., Hooge, M. N. L., de Vries, E. G. E., & Kosterink, J. G. W. (2018) · Medicinal Research Reviews · doi:10.1002/med.21498 · Cited by 20
van Scheltinga, A. G. T. T., Berghuis, P., Nienhuis, H. H., Timmer‐Bosscha, H., Pot, L., Gaykema, S. B. M., Hooge, M. N. L., Kosterink, J. G. W., de Vries, E. G. E., & Schröder, C. P. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.06.008 · Cited by 19
Identification of Ligands and Translation to Clinical Applications
Haberkorn, U., Mier, W., Kopka, K., Herold‐Mende, C. C., Altmann, A., & Babich, J. W. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.186791 · Cited by 19
Synergistic Killing Effect between Vorinostat and Target of CD146 in Malignant Cells
Ma, X., Liu, J., Wu, J., Yan, X., Wu, P., Liu, Y., Li, S., Tian, Y., Cao, Y., Chen, G., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3174 · Cited by 18
Self-citationImaging EGFR and HER3 through 89Zr-labeled MEHD7945A (Duligotuzumab)
McKnight, B. N., Kuda‐Wedagedara, A. N. W., Sevak, K. K., Abdel-Atti, D., Wiesend, W. N., Ku, A. T., Selvakumar, D., Carlin, S. D., Lewis, J. S., & Viola, N. T. (2018) · Scientific Reports · doi:10.1038/s41598-018-27454-6 · Cited by 18
Site-Specific Radioactive Labeling of Nanobodies
Crauwels, M., Massa, S., Martin, C., Betti, C., Ballet, S., Devoogdt, N., Xavier, C., & Muyldermans, S. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8648-4_26 · Cited by 18
Wiehr, S., Bühler, P., Gierschner, D., Wolf, P., Rolle, A.-M., Kesenheimer, C., Pichler, B. J., & Elsässer‐Beile, U. (2014) · The Prostate · doi:10.1002/pros.22794 · Cited by 17
Pool, M., Kol, A., Hooge, M. N. L., Gerdes, C. A., de Jong, S., de Vries, E. G. E., & van Scheltinga, A. G. T. T. (2016) · Oncotarget · doi:10.18632/oncotarget.11827 · Cited by 17
Antibody-based PET of uPA/uPAR signaling with broad applicability for cancer imaging
Yang, D., Severin, G. W., Dougherty, C. A., Lombardi, R. L., Chen, D., Dort, M. E. V., Barnhart, T. E., Ross, B. D., Mazar, A. P., & Hong, H. (2016) · Oncotarget · doi:10.18632/oncotarget.12528 · Cited by 17
Maruthachalam, B. V., El‐Sayed, A., Liu, J., Sutherland, A. R., Hill, W., Alam, M. K., Pastushok, L., Fonge, H., Barreto, K., & Geyer, C. R. (2017) · ChemBioChem · doi:10.1002/cbic.201700279 · Cited by 17
Self-citationVorobyeva, A., Westerlund, K., Mitran, B., Altai, M., Rinne, S. S., Sörensen, J., Orlova, A., Максимилианович, Т. В., & Karlström, A. E. (2018) · Scientific Reports · doi:10.1038/s41598-018-27886-0 · Cited by 17
Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate
Brand, C., Sadique, A., Houghton, J. L., Gangangari, K. K., Ponte, J. F., Lewis, J. S., Pillarsetty, N., Konner, J. A., & Reiner, T. (2018) · EJNMMI Research · doi:10.1186/s13550-018-0437-x · Cited by 17
ImmunoPET imaging of CD38 expression in hepatocellular carcinoma using 64Cu-labeled daratumumab.
Li, S., England, C. G., Ehlerding, E. B., Kutyreff, C. J., Engle, J. W., Jiang, D., & Cai, W. (2019) · PubMed · Cited by 17
Self-citationSel-tag imaging project, Cheng, Q., Wållberg, H., Grafström, J., Lu, L., Thorell, J.-O., Olofsson, M. H., Linder, S. T., Johansson, K., Tegnebratt, T., et al. (2016) · EJNMMI Research · doi:10.1186/s13550-016-0213-8 · Cited by 16
Pool, M., de Boer, H. R., Hooge, M. N. L., van Vugt, M. A. T. M., & de Vries, E. G. E. (2017) · Theranostics · doi:10.7150/thno.17934 · Cited by 16
Foubert, F., Gouard, S., Maurel, C., Chérel, M., Faivre-Chauvet, A., Goldenberg, D. M., Barbet, J., Bailly, C., Bodet‐Milin, C., Carlier, T., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25514 · Cited by 16
MT1-MMP as a PET Imaging Biomarker for Pancreas Cancer Management
Morcillo, M. Á., de Lucas, Á. G., Oteo, M., Romero, E., Magro, N., Ibanez-Moragues, M., Martínez, A., Garaulet, G., Arroyo, A. G., Lopez-Casas, P. P., et al. (2018) · Contrast Media & Molecular Imaging · doi:10.1155/2018/8382148 · Cited by 15
Adams, H., van de Garde, E. M. W., van Moorsel, C. H. M., Vugts, D. J., van Dongen, G. A. M. S., Grutters, J. C., & Keijsers, R. G. M. (2019) · Europe PMC (PubMed Central) · Cited by 15
Skovgaard, D. C., Persson, M., & Kjær, A. (2016) · Clinical and Translational Imaging · doi:10.1007/s40336-016-0197-4 · Cited by 12
Maier, F. C., Schmitt, J., Maurer, A., Ehrlichmann, W., Reischl, G., Nikolaou, K., Handgretinger, R., Pichler, B. J., & Thaiss, W. M. (2016) · Oncotarget · doi:10.18632/oncotarget.11795 · Cited by 12
In vivo imaging of TGFβ signalling components using positron emission tomography
Rotteveel, L., Poot, A. J., Bogaard, H. J., ten Dijke, P., Lammertsma, A. A., & Windhorst, A. D. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.08.011 · Cited by 11
Maier, F. C., Wild, A., Kirchen, N., Holm, F., Fuchs, K., Schwenck, J., Maurer, A., & Wiehr, S. (2018) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2018.09.006 · Cited by 10
Duvenhage, J., Ebenhan, T., Garny, S., González, I. H., Montaña, R. L., Price, R. I., Birkholtz, L., & Zeevaart, J. R. (2019) · Molecular Imaging and Biology · doi:10.1007/s11307-019-01360-3 · Cited by 6
Cited by
Antibody–Drug Conjugates for Cancer Therapy
Hafeez, U., Parakh, S., Gan, H. K., & Scott, A. M. (2020) · Molecules · doi:10.3390/molecules25204764 · Cited by 395
Guo, X., Li, Y., Zhang, M., Cao, K., Tian, Y., Qi, Y., Li, S., Li, K., Yu, X., & Ma, L. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202010829 · Cited by 345
Radiochemistry for positron emission tomography
Rong, J., Haider, A., Jeppesen, T. E., Josephson, L., & Liang, S. H. (2023) · Nature Communications · doi:10.1038/s41467-023-36377-4 · Cited by 294
Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities
Pauken, K. E., Dougan, M., Rose, N. R., Lichtman, A. H., & Sharpe, A. H. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.04.002 · Cited by 280
Biomarkers for immunotherapy of hepatocellular carcinoma
Greten, T. F., Villanueva, A., Korangy, F., Ruf, B., Yarchoan, M., Ma, L., Ruppin, E., & Wang, X. W. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00816-4 · Cited by 227
“A variety of radionuclides and monoclonal antibodies have been used to develop immunoPET probes, which has been driven by advances in radiochemistry and conjugation strategies 152 .”
Background
Metadata
- Authors
- Wei, W., Rosenkrans, Z. T., Liu, J., Huang, G., Luo, Q.-Y., & Cai, W.
- Venue
- Chemical Reviews
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-03-23
- Volume
- 120
- Issue
- 8
- Pages
- 3787-3851
- ISSN
- 0009-2665 (ISSN-L)
- 1520-6890
- OpenAlex
- W3012903956
- Cited by
- 484
- References
- 717
- FWCI
- 12.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.